As of September 2023 it is on the FDA Category 2 list of bulk drug substances that may not be compounded, and a PCAC review is scheduled for July 2026 under the name Emideltide
The compounding process ensures that the medication meets the unique needs and specifications of each patient
If youre ready to start your weight loss journey with GLP-1 in OKC, contact us to schedule an appointment at either our Edmond or our Oklahoma City location
Ringenberger K, Kaufman B, Rosilio M, Turakhiya A, Liao B
Contact your local blood bank directlypolicies vary, and some centers are developing updated protocols for GLP-1 donors
People should always work their physician to determine what works for them based on their history, Novo Nordisk says in a statement when asked about this issue